-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Nanjing Chia Tai Tianqing entered the administrative approval stage with Mirabegron extended-release tablets, which are imitated Category 4, and is expected to be approved for marketing in the near future
.
Mirabegron is a selective β3-adrenergic receptor agonist with global sales of 163.
6 billion yen in 2020, and was included in the second batch of encouraged generic catalogs
.
Mirabegron is a selective β3-adrenergic receptor agonist developed by Astellas, which is mainly used to treat urinary urgency, frequency and incontinence caused by overactive bladder
.
The product was first approved for listing in Japan in September 2011, and was approved for listing in China in December 2017
.
Since its listing, the global market of Mirabegron has shown an upward trend year by year.
In 2020, the global sales of Astellas' Mirabegron extended-release tablets were 163.
6 billion yen (about 1.
538 billion US dollars, according to the average exchange rate in 2020)
.
According to data from Minet.
com, Mirabellon's Chinese market is in the development stage.
In 2020, the terminal sales of physical pharmacies in Chinese cities will exceed 15 million yuan, a year-on-year increase of 152.
34%
.
Sales of Mirabegron in Chinese urban physical pharmacies (unit: RMB 10,000) Source: Minet Yi Pharmaceutical, Nanjing Zhengda Tianqing, Qilu Pharmaceutical, CSPC, Sichuan Guowei Pharmaceutical, Shenzhen Wanle Pharmaceutical
.
On April 13, 2021, Zhejiang Huayi Pharmaceutical's Mirabegron Sustained-Release Tablets was approved for marketing and won the first domestic imitation
.
The registration status of Nanjing Chia Tai Tianqing’s product has been changed to “under approval”.
If it is successfully approved, it will be regarded as a review and become the second domestic company
.
Data source: Minet database, NMPA Note: Minet China's urban physical pharmacy terminal competition pattern database is an enlarged version of continuous monitoring of all categories covering physical pharmacies in 297 cities and above across the country (excluding county and rural physical pharmacies).
A database of urban brick-and-mortar pharmacies
.
The above sales are calculated based on the average retail price of the product in the terminal
.
.
Mirabegron is a selective β3-adrenergic receptor agonist with global sales of 163.
6 billion yen in 2020, and was included in the second batch of encouraged generic catalogs
.
Mirabegron is a selective β3-adrenergic receptor agonist developed by Astellas, which is mainly used to treat urinary urgency, frequency and incontinence caused by overactive bladder
.
The product was first approved for listing in Japan in September 2011, and was approved for listing in China in December 2017
.
Since its listing, the global market of Mirabegron has shown an upward trend year by year.
In 2020, the global sales of Astellas' Mirabegron extended-release tablets were 163.
6 billion yen (about 1.
538 billion US dollars, according to the average exchange rate in 2020)
.
According to data from Minet.
com, Mirabellon's Chinese market is in the development stage.
In 2020, the terminal sales of physical pharmacies in Chinese cities will exceed 15 million yuan, a year-on-year increase of 152.
34%
.
Sales of Mirabegron in Chinese urban physical pharmacies (unit: RMB 10,000) Source: Minet Yi Pharmaceutical, Nanjing Zhengda Tianqing, Qilu Pharmaceutical, CSPC, Sichuan Guowei Pharmaceutical, Shenzhen Wanle Pharmaceutical
.
On April 13, 2021, Zhejiang Huayi Pharmaceutical's Mirabegron Sustained-Release Tablets was approved for marketing and won the first domestic imitation
.
The registration status of Nanjing Chia Tai Tianqing’s product has been changed to “under approval”.
If it is successfully approved, it will be regarded as a review and become the second domestic company
.
Data source: Minet database, NMPA Note: Minet China's urban physical pharmacy terminal competition pattern database is an enlarged version of continuous monitoring of all categories covering physical pharmacies in 297 cities and above across the country (excluding county and rural physical pharmacies).
A database of urban brick-and-mortar pharmacies
.
The above sales are calculated based on the average retail price of the product in the terminal
.
